EUVIMEDEUVIMED entdecken
Übersichtsarbeit

CCR8: a promising therapeutic target against tumor-infiltrating regulatory T cells

Yuanjia Wen, Yu Xia, Xiangping Yang, Huayi Li, Qinglei Gao

Trends in Immunology · 2025-02 · 46 (2) · 153-165

DOI: 10.1016/j.it.2025.01.001 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Trends in Immunology, 2025-02. Verfasst von Yuanjia Wen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, National Clinical Research Center for Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Hu…. Hauptthemen laut MEDLINE: T-Lymphocytes, Regulatory, Neoplasms, Lymphocytes, Tumor-Infiltrating, Receptors, CCR8. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 89 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Beijing Xisike Clinical Oncology Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumor-infiltrating regulatory T (TI-Treg) cells constitute key components within the tumor microenvironment (TME) to suppress antitumor immunity and facilitate tumor progression. Although multiple therapies have been developed to eliminate TI-Treg cells, most of them exhibit only modest efficacy and harbor risks of inducing immune-related adverse events (irAEs). Recent studies demonstrate that CC chemokine receptor (CCR)8 is highly and specifically expressed on effector TI-Treg cells in mice and humans, highlighting CCR8 as a promising target for selective TI-Treg cell depletion in the treatment of various cancers. Here, we concentrate on the latest understanding of CCR8 regarding its expression, functions, and regulation, and summarize the current landscape of CCR8-targeted therapies. With favorable efficacy and safety, the latter represent an important class of next-generation putative cancer immunotherapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

T-Lymphocytes, RegulatoryNeoplasmsLymphocytes, Tumor-InfiltratingReceptors, CCR8ImmunotherapyHumansAnimalsTumor MicroenvironmentMolecular Targeted Therapy

Stichwörter der Autor:innen

CCR8cancer therapeuticsimmunotherapyregulatory T cellstumor immunity

Substanzen

Receptors, CCR8CCR8 protein, human

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, National Clinical Research Center for Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Key Laborat…
  • The Second Affiliated Hospital of Guangzhou Medical University, Guangdong Provincial Key Laboratory of Allergy and Clinical Immunology, Guangzhou, China.

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Beijing Xisike Clinical Oncology Research Foundation

Zitieren

APA

Wen, Y., Xia, Y., Yang, X., Li, H., & Gao, Q. (2025). CCR8: a promising therapeutic target against tumor-infiltrating regulatory T cells. Trends in Immunology, 46(2), 153-165. https://doi.org/10.1016/j.it.2025.01.001

Vancouver

Wen Y, Xia Y, Yang X, Li H, Gao Q. CCR8: a promising therapeutic target against tumor-infiltrating regulatory T cells. Trends in Immunology. 2025;46(2):153-165. doi:10.1016/j.it.2025.01.001

BibTeX
@article{Wen2025,
  author = {Wen, Yuanjia and Xia, Yu and Yang, Xiangping and Li, Huayi and Gao, Qinglei},
  title = {CCR8: a promising therapeutic target against tumor-infiltrating regulatory T cells},
  journal = {Trends in Immunology},
  year = {2025},
  volume = {46},
  number = {2},
  pages = {153--165},
  doi = {10.1016/j.it.2025.01.001}
}
Kostenlos starten →